Home/Pipeline/Glaucoma Program

Glaucoma Program

Glaucoma

Pre-clinicalActive

Key Facts

Indication

Glaucoma

Phase

Pre-clinical

Status

Active

Company

Broadwing Bio

About Broadwing Bio

Broadwing Bio is a private, pre-clinical stage biotech developing antibody therapies for Geographic Atrophy and Glaucoma, two leading causes of irreversible blindness with significant unmet need. The company leverages a genetics-centric discovery platform, building on insights from human genetic variants, and utilizes the antibody generation capabilities of its strategic partner, Alloy Therapeutics. Founded by veterans from Genentech and Calico, Broadwing is assembling a team with deep drug discovery expertise to advance its mission of ending blindness.

View full company profile

Therapeutic Areas

Ophthalmology Retinal Diseases Neurodegenerative Eye Disease

Other Glaucoma Drugs

Drug	Company	Phase	Status
PREZIA Glaucoma Implant	PolyActiva	Preclinical	Active
MIGS Device System	Micropoint Biotechnologies	Commercial	Market approved in China
INM-088	InMed Pharmaceuticals	Preclinical	Active
OT-401	Ocumension Therapeutics	Phase 2	Active
ANX007	Annexon Biosciences	Phase 2	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
MediPrint Lens (Glaucoma)	MediPrint Ophthalmics	Phase 2b	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
BTQ1902	Betaliq	Phase 2	Active
TODDD™ Platform	Amorphex Therapeutics	Pre-clinical	Active